Category: Science

  • Shots on Goal

    Shots on Goal

    Two tobacco plant-based vaccine candidates have entered the race for a serum against Covid-19.

    By Stefanie Rossel

    Photos: British American Tobacco

    As the coronavirus pandemic continues to take a devastating toll around the world, the race for a vaccine against Covid-19 among pharmaceutical and biotech companies, universities, research institutes and other stakeholders has accelerated. According to a report by Verband Forschender Arzneimittelhersteller, the German association of researching drug manufacturers, there were more than 70 vaccine projects for the novel coronavirus SARS-CoV-2 globally in early April. The aim of such a vaccine is to create an adaptive immune response in the form of antigens in the vaccinated person that will protect against an invading microorganism and the disease it causes, in this case an infection with the coronavirus. Vaccines, which are biological preparations, are considered the most effective preventive measures against infectious diseases.

    Coronaviruses, a group of viruses that belong to the family Coronaviridae, have always been around. Infections caused by other members of that family include severe acute respiratory syndrome (SARS), which appeared in 2002 to 2003, and the Middle East respiratory syndrome (MERS), which appeared in September 2012. On both occasions, vaccines were developed, but to date, none of them has received drug approval—in comparison with other infectious diseases, such as influenza and HIV, SARS and MERS produced relatively few and locally restricted cases, thus lowering the willingness to further invest in vaccine development. Nevertheless, this earlier research may now help scientists in their quest for an antidote against SARS-CoV-2, which, with its high transmission rate and resulting numerous deaths, is of a different caliber.

    To combat the novel virus, scientists have a range of processes at their disposal. Depending on the disease-causing agents, how it infects the cell and how the immune system responds to it, they decide which type of vaccine might be the most promising. Current options include live attenuated vaccines, which use a weakened form of the virus or bacteria that causes a disease, and inactivated vaccines that contain bacteria or viruses that have been killed by a chemical treatment or heat. Subunit, recombinant, polysaccharide and conjugate vaccines use specific pieces of the virus or bacteria—like its protein, sugar or capsid. Finally, toxoid vaccines use a toxin made by the virus or bacteria that causes a disease.

    In the production of vaccines, embryonated chicken eggs play an important role. In 1931, they were discovered to be the perfect bioreactors for growing viruses and thus the best tool to produce vaccines. Almost 90 years later, 95 percent of all flu vaccine doses still contain egg-grown viruses, according to the German Max Planck Society. It’s easy to imagine that this production process will quickly near its limits in the case of a pandemic that affects millions of people.

    Advertisement

    Tobacco as a bioreactor

    Enter tobacco. Since the early 2000s, the plant has proven its potential as a highly efficient biopharmaceutical producer of vaccines—more precisely, of recombinant therapeutical proteins. Basically, the process involves identification and reception of genetic sequences from a pandemic strain to produce a virus-like particle (VLP). VLPs resemble a virus, allowing them to be recognized readily by the immune system; however, they lack the core genetic material, making them noninfectious and unable to replicate. Before the genetic construct representing the protein of interest is inserted, plants are seeded, germinate and grow. They are then genetically modified with the VLP—or antigen—in a technique known as transient expression. With this transformation, plants incubate for several days during which they are reproducing the target protein. At this point, they are harvested and crushed to create a green juice slurry. This liquid passes through filtration processes and sophisticated purification techniques to produce a final product. Reportedly, the process, which employs Nicotiana benthamiana, a close relative of the tobacco type used for cigarette manufacture, can deliver a vaccine for testing in less than a month after production of the VLP.

    In a virus outbreak such as the current one, rapid serum production of scale is vital. Two biopharmaceutical companies working with tobacco-based systems joined the race early on for a vaccine. Medicago, a privately held Canadian biotech company in which Philip Morris International bought a stake in 2008, in April announced that its candidate coronavirus vaccine could be ready for human trials by July or August; the company plans to submit a dossier to authorities to get approval for the drug by November 2021.

    Kentucky Bioprocessing’s plant-based vaccine has several potential advantages over conventional serum production technology, including safety, speed of development and stability at room temperature.

    Advantages over conventional technologies

    David O’Reilly

    The other player is U.S.-based Kentucky Bioprocessing (KBP), a subsidiary of British American Tobacco (BAT). The company’s candidate vaccine uses BAT’s proprietary fast-growing plant technology and TAP platform, a new system for vaccine production that allows antigen selection closer to the time it is needed to avoid mutations. The serum is presently also in the pre-clinical testing phase that is expected to finish soon. “We have been engaging with government agencies to bring our candidate vaccine to clinical testing as soon as possible,” explains David O’Reilly, BAT’s director of scientific research. On May 15, the company announced that it was ready to start testing its vaccine on humans once it gets approval from the U.S. Food and Drug Administration (FDA).

    Through collaborations with government and third-party manufacturers, KBP hopes to produce between 1 million and 3 million doses per week from June, says O’Reilly. “We will be ready to start clinical trials in late June and start manufacturing in parallel. It is impossible to say when it will be available, and this will become clearer when we know what testing governments will require.”

    The plant-based vaccine has several potential advantages over conventional serum production technology, according to O’Reilly. “It is potentially safer given that tobacco plants can’t host pathogens which cause human disease. It is faster because the elements of the vaccine accumulate in tobacco plants much more quickly and with high fidelity—six weeks in tobacco plants versus several months using conventional methods. The vaccine formulation KBP is developing remains stable at room temperature, unlike conventional vaccines, which often require refrigeration. And it reproduces the antigen with high fidelity every time without making unwanted changes.”

    He is not worried about the frequent headlines about the progress of other conventional vaccine manufacturers. “This is noncompetitive, and BAT is fully prepared to work with other vaccine companies with our unique vaccine development technologies,” says O’Reilly. “As such, BAT is looking for help from governments to accelerate clinical trials to demonstrate the candidate vaccine is safe and effective. We also need help with downstream manufacturing in terms of conjugation and dispensing and are open to working with governments and other partners to build scaled-up manufacturing.”

    Advertisement

    Long-winded approval process

    Even though other candidate vaccines appear to be one step ahead, it doesn’t mean that they will be the first and only ones that become approved and commercially available. Each new vaccine project must go through a six-stage process to get approval by the FDA or the European Medicines Agency. The stages include analysis of the virus, design of the vaccine and animal testing in the pre-clinical phase, which is followed by trials with volunteers, approval procedure and mass production of the vaccine. Although the process has been significantly accelerated in recent years due to new technology and previous experience with serum developments against related viruses, it may nevertheless take up to 36 months—under normal conditions. Will the unprecedented dimensions of the Covid-19 pandemic speed up matters?

    “Testing any vaccine candidate for safety and efficacy is paramount. This requires extensive and complex clinical testing and evaluation of the results,” O’Reilly explains. “During clinical testing and through pharmacovigilance, i.e., drug safety assessment, potential side effects can be identified. If they are serious then this is likely to mean the vaccine will not be authorized for use. Under pandemic emergency situations, regulators have the option of ‘emergency use authorization.’ The U.S. FDA authorized our ZMapp Ebola treatment through this pathway in 2014.”

    Together with Mapp Biopharmaceutical, KBP developed an Ebola drug that came to be considered the standard of care after a small study suggested it might reduce mortality rates. Long-term studies, however, showed that the treatment didn’t provide the anticipated degree of protection, so it failed to receive permanent approval.

    Each new vaccine project must go through a six-stage process to get approval by the FDA or the European Medicines Agency.

    Costly development

    Time can become the decisive hurdle in drug development. History has shown that the search for a suitable vaccine sometimes is too slow: In 2009, the swine flu outbreak quickly waned, leaving drug makers sitting on their vaccine. “That’s a real problem and it remains to be seen how quickly vaccines can be developed, tested and approved in the case of Covid-19,” says O’Reilly. “We must also remember that there are other lines of attack being developed such as treatments to reduce the effects of the disease once contracted. There’s also an emerging view that SARS-CoV-2 may be with us for some time and return every year in the way that the seasonal flu virus does. If this happens then vaccines will play an important role.”

    Historically, just 6 percent of vaccine candidates end up making it to market, according to a Reuters report. “Vaccine development is tremendously challenging and complex. Most candidates will fail during development, so it’s great news that so many candidates are being developed for Covid-19. Of the 75 plus in development, hopefully enough will succeed to cover the world’s needs,” says O’Reilly.

    Developing a vaccine is also an enormous investment. According to the U.S. Biomedical Advanced Research and Development Authority, development of a vaccine and treatment will cost $1 billion each. “We are in the early days of this, and the costs are not yet significant. Total costs will become clearer when we better understand the testing requirements going forward,” says O’Reilly.

    While remaining a commercial operation, KBP intends to carry out its Covid-19 vaccine work on a not-for-profit basis. “The most important issue here is to find a vaccine that beats the virus,” O’Reilly says. “It is about collaboration for the greater good and the benefit of society at large. That’s why for Covid-19, we are operating on a ‘not-for-profit’ basis.”

  • Coresta Extends Abstract Submission Deadline

    Coresta Extends Abstract Submission Deadline

    Photo: manekj from Pixabay

    Coresta extends abstract submission deadline

    In response to the coronavirus disruption and numerous requests, Coresta has extended the deadline for submitting abstracts for its 2020 Congress to June 1.

    Abstracts can be submitted online.

    The Coresta Congress will be held at the Hilton Vienna Hotel in Vienna, Austria, Oct. 11–15, 2020, at the invitation of the Japan Tobacco Group.

  • ‘Vaping Less Likely Long-Time Habit’

    ‘Vaping Less Likely Long-Time Habit’

    Photo: Hazem Mohamad

    While the use of e-cigarettes is increasing, vaping is less likely to lead to a long-term habit than smoking, according to a group of 10 interrelated papers prepared for the ongoing Population Assessment of Tobacco and Health (PATH) study.

    “The most surprising finding was that while we know cigarette smoking is persistent, and we see use of electronic cigarettes, or e-cigarettes, increasing, especially among young people, what we are not seeing is that e-cigarette use is anywhere near as persistent as cigarette smoking,” says Andrew Hyland, chair of health behavior at Roswell Park and scientific lead on the PATH study.

    “Cigarette smokers tend to stay cigarette smokers over time, but e-cigarette users are more likely to discontinue their use over time compared with cigarette smokers. We don’t know why that is.”

    Hyland speculates that cigarettes deliver nicotine more effectively than e-cigarettes. Studies have shown that the types of e-cigarettes used during the data-collection period from 2013 to 2016 didn’t deliver nicotine as efficiently as cigarettes.

    The study also found that e-cigarette use is associated with attempting to quit smoking. E-cigarette users were 20 percent more likely to try quitting cigarette smoking than adult smokers who did not use e-cigarettes.

  • Covid-19 Vaccine Ready for Human Trials, Says BAT

    Covid-19 Vaccine Ready for Human Trials, Says BAT

    Photo: Pete Linforth | PixaBay

    British American Tobacco (BAT) said on Friday it is ready to test its potential Covid-19 vaccine using proteins from tobacco leaves on humans, after it generated a positive immune response in pre-clinical trials, reports Reuters.

    Once it gets approval from the U.S. Food and Drug administration (FDA) for the vaccine, the company plans to start testing on humans.

    In April BAT announced it was developing a Covid-19 vaccine from tobacco leaves and could produce 1 million to 3 million doses per week if it got the support of government agencies and the right manufacturers.

    Multiple companies from a variety of sectors have been racing to develop a vaccine for Covid-19, with some of the vaccines already in human trials. Experts have suggested that a Covid-19 vaccine could take 12-18 months to develop.

    On Friday, BAT said it had submitted a pre-investigative new drug application to the FDA and that the agency had acknowledged the submission. BAT said it was also talking with other government agencies around the world about the vaccine.

    The company said it has committed funds to conduct clinical trials, which it expects to start as early as late June. BAT has reportedly also invested in additional equipment to boost capacity.

  • WHO: Smoking Does Not Prevent Covid-19

    WHO: Smoking Does Not Prevent Covid-19

    Image by 4924546 from Pixabay

    World Health Organization (WHO) officials stated that smoking does not protect individuals from contracting Covid-19, contrary to some studies that have surfaced stating the opposite.

    “There are some media reports on studies that have not been peer-reviewed that have looked at smoking prevalence among people hospitalized with Covid-19,” said epidemiologist Maria Van Kerkhove, technical lead on Covid-19 response at the WHO Health Emergencies Program. “These studies were not designed to evaluate whether smoking was protective or not in any shape or form. And they do not say that smoking is protective.

    “The harms of tobacco are well known, and we know that millions of people die every year from tobacco use. Covid-19 is a respiratory illness, and smoking causes damage to the lungs,” she said. “A number of studies have found that smoking leads to the development of severe diseases and puts people at higher risk of being put on a ventilator, being admitted to intensive care and eventually of dying. We know the harms of smoking and we know that smokers, if they do get infected with Covid-19, have a higher risk of severe disease and death.”

  • Scientists Urge Caution With Smoking-and-Covid Claims

    Scientists Urge Caution With Smoking-and-Covid Claims

    Image by maja7777 from Pixabay

    Recent studies that have found a disproportionally low number of smokers among Covid-19 patients have not provided direct evidence that smoking is protective against the illness, according to Health Feedback, a nonpartisan, nonprofit organization dedicated to science education.

    Claims that smoking might protect against Covid-19 have been reported in several media outlets and are currently going viral, with more than 410,000 interactions on Facebook in April 2020.

    However, the Health Feedback scientists point out several problems with findings. A French study, for example, did not appropriately factor in comorbidities such as diabetes and hypertension, which can also adversely affect the clinical course of Covid-19, according to the Health Feedback scientists.

    “While the preprint did report the prevalence of such conditions within the combined study cohort of inpatients and outpatients, it did not report age or disease prevalence according to smoking status,” they wrote. “It is therefore unclear whether the nonsmoking group comprised more older individuals and/or those with preexisting health conditions than the other, which might have influenced the results.”

    Other studies showed similar shortcomings, according to the Health Feedback scientists.

    While acknowledging that the findings of disproportionally low numbers of smokers among Covid-19 patients are interesting and deserving of further investigation, the Health Feedback scientists say it would be unwise to begin smoking based on unproven claims that it might protect against Covid-19.
     

  • Methods for Lower Nicotine Validated

    Methods for Lower Nicotine Validated

    Photo: Matt Mullen

    22nd Century Group and North Carolina State University (NCSU), have completed successful research field trials that have validated new non-GMO methodologies for reducing nicotine in tobacco plants. The research was partially funded by 22nd Century and was conducted by NCSU’s Department of Crop and Soil Science with project oversight provided by 22nd Century’s R&D team.

    The research findings and paper can be viewed here.

    As an alternative to older, genetic-engineering technologies that result in the creation of plants regulated as GMOs, the NCSU researchers used newer, non-CRISPR, non-GMO, gene editing technologies to consistently achieve reductions in nicotine levels by as much as 99 percent, when compared to conventional tobacco plants. This reduction in nicotine levels is believed to be caused by the inactivation of several genes believed to encode for enzymes involved in nicotine biosynthesis in the plant. 22nd Century has earlier filed a patent application with the U.S. Patent and Trademark Office to secure intellectual property rights for this non-GMO genetic approach that achieves very low nicotine content (VLNC) levels in tobacco plants using non-GMO methodologies.

    “We are very pleased with the outcome of the research field trials completed in collaboration with NCSU, which demonstrate that non-GMO methodologies can be applied reliably to reduce nicotine levels in tobacco plants by up to 99 percent,” said Juan Sanchez Tamburrino, vice president of research and development for 22nd Century. “To further validate our research, 22nd Century and NCSU will conduct larger scale and more extensive field trials in additional geographies.”

    The additional field trials will test these new, non-GMO, VLNC tobacco lines in multiple locations and soil conditions, allowing 22nd Century to select VLNC tobacco plants for optimal performance in different locations.

    “This research marks a key milestone in 22nd Century’s reduced nicotine content tobacco R&D program and further extends our product development opportunities by enabling the creation of VLNC tobacco plants of many varieties, including bright, burley and oriental tobaccos,” said Michael Zercher, 22nd Century’s president and chief operating officer. “This non-GMO technology is also key to commercializing our VLNC tobacco cigarettes in international markets where non-GMO products are important. We are pleased with our R&D team’s progress and excited about this unique technology developed in collaboration with NCSU.”

  • Broughton Expands Toxicology Team

    Broughton Expands Toxicology Team

    Photo courtesy of Broughton Nicotine Services
    Yvonne Wilding

    Broughton Nicotine Services has hired five additional toxicology specialists to strengthen its support for companies in the electronic nicotine delivery systems (ENDS) sector.

    The new team members are: Yvonne Wilding (director, product safety and compliance), Emmanuel Minet and Frazer Lowe (principal scientists), Djeren Simitdjioglu (associate toxicologist) and Anais Kahve (toxicologist).

    Wilding is a highly experienced toxicologist with more than 10 years’ broad regulatory toxicology experience and 20 years pharmaceutical research and development experience at companies such as GlaxoSmithKline and AstraZeneca.

    ‘’We’re delighted to welcome these highly experienced individuals to our existing team,” said Chris Allen, vice president of scientific and regulatory affairs at Broughton. “Toxicology is an essential element of the scientific and regulatory support we provide to ENDS companies submitting premarket applications in the UK, US and emerging markets.

    “Having a large team of toxicologists in-house collaborating with our analytical team and external suppliers will help us leverage improved efficiencies for clients and accelerate compilation of scientific data for regulatory projects to advance a smoke free future.’’

  • Nicotine: Not Quite the Villain It’s Made out to Be

    Nicotine: Not Quite the Villain It’s Made out to Be

    The scientific evidence is clear that nicotine itself is not responsible for smoking-related diseases.

    By Ian Jones

    If you are as old as me, and happen to come from the U.K., you may recall Nick O’Teen, one of the central characters in an anti-smoking campaign run by the U.K. Health Education Council (HEC) in the early 1980s. With his cigarette-butt-shaped top hat and bright yellow teeth, O’Teen was the campaign’s arch villain and was regularly apprehended by the campaign’s hero, Superman.

    Now, obviously, Nick O’Teen’s name is a play on the word “nicotine,” so it is reasonable to assume that people who saw the campaign in the 1980s concluded that nicotine in cigarettes is the direct cause of smoking-related illnesses. In fact, according to recent surveys, this is still a commonly held belief, not only in the U.K. but in several other surveyed countries. But, given what we know today, does nicotine deserve this reputation or, as Mitch Zeller, director of the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products, the agency in the USA responsible for overseeing the implementation of tobacco product regulation, has previously asked, is it time for a “rethink within society on nicotine”?

    Let’s start with the basics: What exactly is nicotine, and what does it do?

    Nicotine is a chemical naturally found in tobacco and other related plants, in the same way that caffeine is naturally found in tea. Why does tobacco produce nicotine? Well, the commonly held belief is that nicotine helps protect the tobacco leaves from being eaten by insects and other predators. It does this in two ways.

    First, nicotine has a bitter taste, so it could make the leaves unpalatable to some potential diners. Second, and of more relevance to its namesake Nick O’Teen, nicotine mimics one of the natural chemicals that cells in the nervous system of animals use to communicate with each other. Thus, eating nicotine-containing leaves could impact the normal working of the nervous system (in fact, this could even be fatal to some insects).

    Now, in you and me, the chemical that nicotine mimics, acetylcholine, is found throughout the nervous system and performs a myriad of functions. In the brain specifically, acetylcholine acts a bit like a volume control dial, turning up or turning down signals between brain cells. Which way the dial is turned depends on the brain region and the state of mind at the time.

    This is why nicotine, by mimicking acetylcholine, is said to not only help with attention (volume up) but also relaxation (volume down). It also explains the addictive property of nicotine. In the part of the brain responsible for identifying enjoyable experiences, nicotine can turn the volume up, making the experience of smoking stronger.

    Herein also lies a very important point; the addictive effects of nicotine are usually paired with a particular enjoyable experience. It explains why one of the common tests for tobacco addiction, the Fagerström Test for Nicotine Dependence, was renamed to the Fagerström Test for Cigarette Dependence; addiction to smoking is not solely due to the addictive nature of nicotine alone, but is a result of the interplay between nicotine, acting as volume up, and a series of sensory and other cues (smell, taste, ritual, etc.).

    But hold on a minute; doesn’t nicotine cause cancer and other diseases associated with smoking?

    This is one of the main misunderstandings about nicotine and the answer is simple—no. The scientific evidence is clear that nicotine itself is not responsible for smoking-related diseases. These are caused by other things in smoke, particularly chemicals formed when tobacco is burnt. Remember, tobacco-derived nicotine is an approved medicine and is even available without prescription in many countries.

    This would not be the case if there were serious health risks associated with its use. Furthermore, the use of tobacco products that are not burned during use, such as Scandinavian snus—a tobacco product that is placed under the consumer’s lip—is associated with much lower risks of developing cancer compared to smoking, even though the product also delivers nicotine to the user. The FDA in the U.S. recently acknowledged this by approving modified-risk claims for certain snus products.

    This is not to say, though, that nicotine is risk free. As mentioned above, it is addictive and can reinforce addiction to certain pleasurable behaviors. By mimicking acetylcholine, it can also affect certain biological processes such as the development of new blood vessels. There are also concerns about the potential effects of nicotine exposure in developing brains, an area that certainly deserves more research focus (as well as effective practical measures to prevent minors from accessing nicotine-containing products).

    OK, so the science to date noes not support the notion that nicotine causes cancer, but what about nicotine salts? I hear they are even worse than nicotine.

    I would contend that this is another misunderstanding, this time in part due to a lack of clear explanation by manufacturers as to what nicotine salts are when they first came onto the market. The key point to remember is that nicotine is nicotine, whether in salt form, nonsalt form (“nicotine base”), naturally derived or synthetic. Nicotine salts are simply nicotine attached to something else, in the same way that cooking salt is sodium attached to chloride (i.e. sodium chloride).

    Whether nicotine attaches to something else is simply down to how acidic the environment is. In acidic environments (e.g. an acidic e-liquid), nicotine is in salt form. At the other end of the scale, in alkaline environments, it is in base form (not attached to anything). In the middle (neutral pH), as in our bodies, nicotine is in a mixture of salt and base forms. An interesting aside is that nicotine salts are therefore not a new discovery; historically, e-liquids have been around neutral pH, so they have in fact always contained some nicotine salts.

    In any case, the fact that our bodies like to maintain a “just so” neutral pH means that, from a biological point of view, the form of the nicotine in the liquid does not really matter much as it will conform to a salt/base mix as soon as it comes in contact with the body. What nicotine salts (and acidic e-liquids in general) do is provide a different sensory experience, especially at higher nicotine levels, which some consumers may prefer.

    So, back to Nick O’Teen. Does he deserve his reputation? In my opinion, he was an arch villain of his time. As we’ve gained more understanding over the intervening years about the effects of nicotine in the body, I think we can indeed rethink the role of nicotine in society, just as Mitch Zeller suggests. Nicotine is not risk free and is certainly not something that minors should ever consume given concerns about the impact on the developing brain. 

    Likewise, there are other susceptible groups of people, such as pregnant women, that either should not use nicotine-containing products or, at a minimum, seek medical advice before deciding whether to do so. For most adults, however, nicotine deserves acceptance of its new non-villainous persona as a cause of tobacco-related illness, and to be seen as an adult lifestyle choice, the same as many other adult consumer products.

  • Experts: Call for Vape Bans Made Covid-19 Worse

    Experts: Call for Vape Bans Made Covid-19 Worse

    Anti-vaping activist groups continue to use the coronavirus crisis to advance their goal of restricting — or even completely banning — the use of vapor products. They argue that vapers are at higher risk of harm from COVID-19.

    However, the available evidence indicates the opposite: If they had worked to convince more smokers to switch to e-cigarettes, there might be fewer coronavirus-related deaths today, according to a story on insidesources.com.

    That’s the view of Dr. Michael Siegel, professor of community health sciences at the Boston University School of Public Health.

    “It’s absolutely true that if more public health activists had embraced e-cigarettes instead of opposing them and more smokers had been encouraged to switch, there would be less mortality from COVID-19 today,” Siegel told InsideSources. An estimated 2.5 million smokers have given up traditional cigarettes for vaping and other similar technologies.

    Siegel has spent much of his career working to reduce smoking and is no friend of Big Tobacco. At the same time, he embraces the “mitigation over prohibition” model for reducing tobacco use. Anti-tobacco prohibitionists — hoping to get every smoker to “just say no” — are fighting an unwinnable battle, Siegel said, according to the story.

    “What people need to understand is that smoking is such an addictive behavior, and it’s not just the nicotine. It’s the psychology as well. In the middle of a pandemic when people are under so much stress, asking these people to just quit cold turkey is ridiculous,” Siegel said.

    Pointing to claims that smoking and vaping can make coronavirus symptoms worse, some anti-tobacco activists are advocating limits, or even outright bans, on vaping products.

    Earlier this month, Rep. Raja Krishnamoorthi, chairman of the House Subcommittee on Economic and Consumer Policy, sent a letter to the Food and Drug Administration (FDA) asking the agency to “clear the market of e-cigarettes for the duration of the coronavirus pandemic.”

    The New York State Academy of Family Physicians has joined the call for a vaping ban, while other anti-tobacco groups like the Campaign for Tobacco-Free Kids and the Truth Initiative have been advocating restrictions on e-cigarettes for years, according to the story.

    Their efforts create the impression that the risks from traditional cigarettes and e-cigarettes are comparable. And that, Siegel argues, is a dangerous message.

    “There is no evidence for the claim that e-cigarette use has a significant impact on coronavirus patients, that’s just speculation,” Siegel said.

    Dr. Sally Satel, a visiting professor at Columbia University’s Irving Medical Center, agrees. “There is no evidence that vaping causes ‘interstitial lung disease,’ or fibrous scarring. Hundreds of thousands of former smokers have been vaping for at least 10 years to date without evidence of meaningful injury to their lungs,” she writes. “Over the longer-term, it must be said, vaping might cause impairment in lung function — though surely less injury than had vapers continued to smoke.”

    Even supporters of vaping restrictions acknowledge that there is little research involving the novel coronavirus.

    When NYC Mayor Bill de Blasio said “smoking or vaping” contribute to the impact of the coronavirus, Italian medical researcher and former president of the Italian Anti-Smoking League Riccardo Polosa tweeted, “Where is the evidence? Stop placing smoking and vaping on the same level. Get your facts straight, Mayor!”

    Conflating the risks of smoking and vaping is both bad science and discourages smokers from making the switch, health professionals like Siegel argue, according to the story.

    “The impact of smoking on the body’s ability to heal is so significant that most surgeons insist their patients quit prior to surgery because they know that smoking inhibits healing and increases the susceptibility to infection,” Siegel said. There’s no evidence of any similar health impact from vaping.

    If anti-tobacco groups are right about the deadly impact of coronavirus on smokers, then their goal should be to get as many smokers to stop as possible. And a CDC study found that “substituting some cigarettes with e-cigarettes was used by a greater percentage of smokers than the nicotine patch, nicotine gum, or other FDA-approved cessation aids.”

    Siegel makes the case more starkly: “In retrospect, the focus on fighting against e-cigarettes looks terrible. Imagine if, instead of 2.5 million former smokers who made the switch, we were in this coronavirus pandemic with 3 million, 4 million, 5 million ex-smokers. There’s no doubt we would be in better shape today.”